Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anavex Life Sciences, a pharmaceutical company engaged in discovery and development of novel drugs for neurological diseases and cancer, has dosed first healthy human volunteers to evaluate Alzheimer’s disease (AD) compound ANAVEX 2-73 in Phase I clinical trial.
Subscribe to our email newsletter
ANAVEX 2-73 is the first of a new class of oral, disease-modifying drugs being studied to potentially treat AD itself, versus treating its symptoms.
The Phase I clinical trial is a randomized, placebo-controlled study to determine the maximum tolerated single dose, safety, pharmacokinetics, pharmacodynamics of the drug.
Phase I clinical trial is being conducted in Germany in collaboration with ABX-CRO, which has conducted several AD studies at the University of Dresden.
Anavex Clinical Development and Medical Affairs VP Angelos Stergiou said based on several preclinical animal studies, they believe ANAVEX 2-73 is a new anti-Alzheimer’s compound that has the potential to directly address the pathology of AD, potentially halting or even reversing its course.
Dosing of at least 16 healthy volunteers is expected to be complete in approximately three months.